Understanding Carvykti®

Carvykti® (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of patients with relapsed or refractory myeloma after 4 or more prior lines of therapy. Clinical trial data show promising data after 1 to 3 prior lines of therapy. Carvykti uses a patient’s own T cells, which are collected and genetically modified, then infused back into the patient to bind to a protein on myeloma cells, destroy those cells, thereby eliminating the myeloma cells.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.